Sign In
Buy CDXS
$1.40
-0.0800 (-5.41%)
At Close: Jul 31, 2026
Codexis to Report Second Quarter 2026 Financial Results on August 11
09:00am, Tuesday, 28'th Jul 2026
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today
Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)
08:15am, Sunday, 26'th Jul 2026
CDXS is now shifting toward differentiated enzymes and ECO Synthesis, which I think could pay off as commoditized small molecules become less attractive. We've now seen a customer manufacturing order,
Codexis Announces Pricing of Public Offering of Common Stock
11:47pm, Thursday, 23'rd Jul 2026
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide ther
Codexis Announces Proposed Public Offering of Common Stock
04:13pm, Thursday, 23'rd Jul 2026
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide thera
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
02:41pm, Friday, 08'th May 2026
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
08:11pm, Thursday, 07'th May 2026
Codexis (CDXS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.25 per share a year ago.
Codexis Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis m
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Thursday, 30'th Apr 2026
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis to share RNA manufacturing advances at TIDES USA
09:00am, Wednesday, 29'th Apr 2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
01:33pm, Thursday, 12'th Mar 2026
Codexis, Inc. delivered strong FY25 results, with revenue up 19% to $70.4M, driven by a $37.8M technology transfer agreement with Merck. CDXS's ECO Synthesis platform targets the expanding siRNA/RNA t
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
01:25am, Thursday, 12'th Mar 2026
Codexis shares jumped 37.8% in after-hours trading after the company reported a profitable fourth quarter and full-year 2025 revenue growth.
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
07:52pm, Wednesday, 11'th Mar 2026
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
06:35pm, Wednesday, 11'th Mar 2026
Codexis (CDXS) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.13 per share a year ago.
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
04:05pm, Wednesday, 11'th Mar 2026
Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway throu
Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf
02:05am, Monday, 09'th Mar 2026
Codexis (NASDAQ: CDXS) President and CEO Alison Moore outlined the company's strategic focus on RNA medicines manufacturing at TD Cowen's 46th Annual Health Care Conference, emphasizing expected infle
